An HBV-HIV Co-infected Patient Treated with Tenofovir-based Therapy who Achieved HBs Antigen/Antibody Seroconversion

作者：Watanabe Takao; Tokumoto Yoshio; Hirooka Masashi; Koizumi Yohei; Tada Fujimasa; Ochi Hironori; Abe Masanori; Kumagi Teru; Ikeda Yoshio; Matsuura Bunzo; Takada Kiyonori; Hiasa Yoichi^*

来源：Internal Medicine, 2014, 53(12): 1343-1346.

DOI：10.2169/internalmedicine.53.2131

• hepatitis B virus
• human immunodeficiency virus
• co-infection
• tenofovir
• seroconversion

The present report describes a case of a patient with hepatitis B virus (HBV)-human immunodeficiency virus (HIV) co-infection who was treated with tenofovir disoproxil (TDF)-based highly active antiretroviral therapy (HAART) and who achieved HBs antigen (Ag)/antibody (Ab) seroconversion. An 18-year-old Japanese man with HIV and HBV co-infection presented to our hospital. His CD4 count was decreased, and TDF-based HARRT was started. At 30 months after initiation of therapy, HBsAg was not detected. At 36 months after initiation of therapy, HBsAb was detected. We conclude that TDF-based therapy is useful for the management of patients with HBV and HIV co-infection.

• 出版日期2014